Comparative Pharmacology
Head-to-head clinical analysis: BUMETANIDE versus ETHACRYNATE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUMETANIDE versus ETHACRYNATE SODIUM.
BUMETANIDE vs ETHACRYNATE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits the Na-K-2Cl symporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.
Ethacrynate sodium inhibits the Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased diuresis.
0.5-2 mg IV/IM/PO once daily; may repeat every 6-8 hours; max 10 mg/day. Continuous IV infusion: 1 mg loading dose, then 0.5-2 mg/hour.
50 mg intravenously once daily; may increase in increments of 25-50 mg as needed, maximum 200 mg/day.
None Documented
None Documented
Clinical Note
moderateBumetanide + Digoxin
"The risk or severity of adverse effects can be increased when Bumetanide is combined with Digoxin."
Clinical Note
moderateBumetanide + Digitoxin
"The risk or severity of adverse effects can be increased when Bumetanide is combined with Digitoxin."
Clinical Note
moderateBumetanide + Deslanoside
"The risk or severity of adverse effects can be increased when Bumetanide is combined with Deslanoside."
Clinical Note
moderateBumetanide + Acetyldigitoxin
Terminal elimination half-life is approximately 1-1.5 hours in healthy adults; prolonged to 1.5-3 hours in renal impairment.
Terminal elimination half-life: 2-4 hours in normal renal function; prolonged to 20-30 hours in end-stage renal disease.
Primarily renal (approximately 80% as unchanged drug), with minimal biliary/fecal excretion (about 10-20%).
Renal: approximately 30% unchanged; biliary/fecal: minor (less than 10%); majority metabolized to cysteine adducts excreted in urine.
Category A/B
Category C
Loop Diuretic
Loop Diuretic
"The risk or severity of adverse effects can be increased when Bumetanide is combined with Acetyldigitoxin."